Searching for the elusive targets of farnesyltransferase inhibitors
- 1 December 2003
- journal article
- Published by Springer Nature in Nature Reviews Cancer
- Vol. 3 (12), 945-951
- https://doi.org/10.1038/nrc1234
Abstract
No abstract availableKeywords
This publication has 71 references indexed in Scilit:
- High Affinity for Farnesyltransferase and Alternative Prenylation Contribute Individually to K-Ras4B Resistance to Farnesyltransferase InhibitorsJournal of Biological Chemistry, 2003
- Farnesyltransferase inhibitors are potent lung cancer chemopreventive agents in A/J mice with a dominant-negative p53 and/or heterozygous deletion of Ink4a/ArfOncogene, 2003
- RhoE Binds to ROCK I and Inhibits Downstream SignalingMolecular and Cellular Biology, 2003
- Rheb is a direct target of the tuberous sclerosis tumour suppressor proteinsNature Cell Biology, 2003
- Rheb is an essential regulator of S6K in controlling cell growth in DrosophilaNature Cell Biology, 2003
- Targeting RAS signalling pathways in cancer therapyNature Reviews Cancer, 2003
- The farnesyltransferase inhibitor, FTI-2153, inhibits bipolar spindle formation during mitosis independently of transformation and Ras and p53 mutation statusCell Death & Differentiation, 2002
- RhoB Is Dispensable for Mouse Development, but It Modifies Susceptibility to Tumor Formation as Well as Cell Adhesion and Growth Factor Signaling in Transformed CellsMolecular and Cellular Biology, 2001
- RhoA Prenylation Is Required for Promotion of Cell Growth and Transformation and Cytoskeleton Organization but Not for Induction of Serum Response Element TranscriptionJournal of Biological Chemistry, 2000
- A novel approach for expression cloning of small GTPases: identification, tissue distribution and chromosome mapping of the human homolog of rhebFEBS Letters, 1995